Cirsium Biosciences Highlights Plant-Based AAV Production Workflow

According to a recent LinkedIn post from Cirsium Biosciences, the company showcased a lighthearted, St. Patrick’s Day–themed look at its plant-based process for producing adeno-associated virus (AAV) vectors. The post walks through images of plants before infiltration, after infiltration when AAV expression occurs, and following homogenization ahead of downstream processing.

The content implies an operational focus on plant-based biomanufacturing of AAV, a modality that could offer scalability and potential cost advantages versus traditional cell culture systems. For investors, the emphasis on defined production stages suggests an established workflow, which may support future capacity expansion, partnerships, or contract development work in the gene therapy manufacturing ecosystem.